Articles tagged "Kidney transplantation"

2022 American Transplant Congress
Multidimensional Immunological Profiling of CMV Dnaemia in Kidney Transplant Recipients
H. Pickering¹, S. Sen², R. S. Ahn², Z. Qian¹, G. Sunga¹, M. LLamas¹, A. Hoffmann¹, M. Deng¹, S. Bunnapradist³, J. Schaenman⁴, D. W. Gjertson¹, M. Rossetti¹, E. Reed⁵
¹UCLA, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Univ of California LA, Los Angeles, CA
*Purpose: Human cytomegalovirus (CMV) infects over half the global population, leading to a mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals…
2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
K. Progar¹, K. Kurwicki², N. Nesselhauf³, J. Hagopian⁴, S. January⁵, H. Wijeweera⁶, M. McCloskey⁷, M. Merzkani⁸, R. Delos Santos⁹
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²SSM Health Saint Louis University Hospital, Saint Louis, MO, ³Barnes-Jewish Hospital, Edwardsville, IL, ⁴Pharmacy, University of Michigan, Ann Arbor, MI, ⁵Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ⁶Washington University, Saint Louis, MO, ⁷Barnes-Jewish Hospital, St. Louis, MO, ⁸Washington University, St Louis, MO, ⁹Transplant, Washington University, St. Louis, MO
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…
2022 American Transplant Congress
Reduced CD45RA-CCR7- Tregs Subtypes in Highly Sensitised Patients Associates with a Failure to Regulate Memory IFNγ Production in Response to Donor Alloantigens
C. Dudreuilh¹, S. Basu¹, O. Shaw², H. Burton¹, C. Domingo-Vila¹, T. Tree¹, G. Lombardi¹, C. Scotta¹, A. Dorling¹
¹King's College London, London, United Kingdom, ²Viapath Clinical Transplantation Laboratory, Guy's Hospital, London, United Kingdom
*Purpose: Highly sensitised (HS) patients exhibit worse long-term outcomes after kidney transplantation compared to non-sensitised patients. It has been hypothesised that regulatory T cells (Tregs)…
2022 American Transplant Congress
NK Cells in Kidney Allograft Antibody-mediated Rejection Display Increased Proliferation, IL-21 Responsiveness, Type-1 Activation, and Cytotoxic Profile
E. Bailly¹, C. Macedo¹, K. Louis², X. Gu¹, B. Ramaswami¹, M. Lucas¹, C. Bentlejewski¹, A. Zeevi¹, P. Randhawa¹, C. Lefaucheur², D. Metes¹
¹Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ²INSERM UMR-S976. Endothelium, Inflammation & Alloreactivity, Paris, France
*Purpose: The role of NK cell during antibody-mediated rejection (ABMR) has been previously recognized, but an in-depth characterization of pathways that contribute to such immune…
2022 American Transplant Congress
A Signature of Tolerance Which Identifies Subclinical Rejection-Free Patients at One Year After Kidney Transplantation
R. Danger¹, L. Le Berre¹, M. Cadoux¹, C. Kerleau¹, P. Guérif¹, E. Morelon², O. Thaunat², C. Legendre³, D. Anglicheau³, K. Renaudin¹, M. Giral¹, S. Brouard¹
¹Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, ITUN, Nantes Université, CHU Nantes, Inserm, Nantes, France, ²Edouard Herriot Hospital, Hospices Civils de Lyon, Inserm U1111, Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France, ³APHP, Necker-Enfants Malades Institute, Inserm, Paris University, Paris, France
*Purpose: Spontaneous and rare cases of patients undergoing a functional renal transplant in the absence of immunosuppression represent a particular situation of immune tolerance. We…
2022 American Transplant Congress
Social Determinants of Health Are Associated with Pre-Emptive Wait Listing and Do Not Fully Account for Racial Gap in Early Access to the Waitlist
A. M. Zehner¹, L. A. Cartwright², T. Mupfudze², T. Wilson², A. Placona², B. Carrico²
¹Research Department, United Network for Organ Sharing, Richmond, VA, ²Research Department, UNOS, Richmond, VA
*Purpose: We leveraged a novel data linkage of candidate-level indicators of social determinants of health (SDOH) among kidney waitlist candidates in the United States to…
2022 American Transplant Congress
Expanded Experience with Ultra-Short Duration Pangenotypic Direct Acting Anti-Viral (DAA) Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic (HCV) Donors to Hepatitis C Negative Kidney Transplant Recipients (KT)
I. Yakubu, D. Kumar, A. Sharma, M. Levy, L. Kamal, G. Gupta
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous studies have shown that HCV D+/R- kidney transplantation is feasible using 8-12 weeks of DAAs. Utilization of abbreviated regimens may obviate the need…
2022 American Transplant Congress
Managing Medications During a Pandemic: A Mixed-Methods Study of Perception of Adult Kidney Transplant Recipients and Those Waiting for a Kidney Transplant
M. R. Wakefield¹, C. M. Ashbaugh², C. Richardson², M. B. Stephens², P. Yerram³, M. Freiburghaus⁴, M. Mercedes⁴, C. L. Russell⁴
¹Surgery/Urology, University of Missouri School of Medicine, Columbia, MO, ²Transplant, University of Missouri Health Care, Columbia, MO, ³Nephrology, Harry S Truman VA Hospital, Columbia, MO, ⁴University of Missouri-Kansas City, Kansas City, MO
*Purpose: Patients interact with healthcare providers (HCP) and pharmacists to manage medications. Little is known about the impact of COVID-19 on medication management. The purpose…
2022 American Transplant Congress
The Financial Burden Of Transplant – A Commercial Claims Analysis
G. Katz-Greenberg¹, O. Osazuwa-Peters¹, J. Gonzalez¹, S. Sanoff¹, O. Oloruntoba¹, N. Chan¹, E. J. Gordon², C. Scales¹, A. Brookhart¹, L. McElroy¹
¹Duke University, Durham, NC, ²Surgery, Northwestern University Feinberg School of Medicine, OAK PARK, IL
*Purpose: Despite access to health insurance, financial concerns are among the most prevalent patient-reported barriers to kidney and liver transplantation (KT and LT, respectively). We…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) for Assessment of Response After Treatment of Allograft Rejection
R. Gohh¹, J. Klein², M. Jagadeesan³, V. Rao⁴, M. Weir⁵, H. Gilligan⁶, G. Shekhtman⁷, N. Agrawal⁸, Y. Fu⁹, E. Akalin¹⁰
¹Alpert School of Medicine, Brown University, Providence, RI, ²University of Kansas Medical Center, Kansas City, KS, ³George Washington School of Medicine, Washington, DC, ⁴Medical University of South Carolina, Charleston, SC, ⁵University of Maryland, Baltimore, MD, ⁶Massachusetts General Hospital, Boston, MA, ⁷CareDx Inc., Brisbane, CA, ⁸CareDx Inc, Brisbane, CA, ⁹CareDx, Brisbane, CA, ¹⁰Montefiore Medical Center, Bronx, NY
*Purpose: Surveillance of dd-cfDNA after therapy for rejection represents a promising strategy for monitoring post-treatment response. We assessed post-rejection kinetics of dd-cfDNA among kidney transplant…